The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.

12 Of the previously published HF data from trials comparing statins to placebo or standard care, only the Heart Protection Study (HPS) demonstrated a reduction in any major HF event, namely a borderline significant reduction of 14% in the composite outcome of HF death and non-fatal HF hospitalization on simvastatin compared with placebo [354 vs. 405 first events, RR 0.86 (95% CI 0.75–1.00)]. 4 In HPS, there were also trends towards reductions in both HF death and non-fatal hospitalizations, respectively. 4 , 33 However, other trials had found no such benefit, underlining the need for a comprehensive synthesis of trial data.

also in 11,409 other papers

Analyses in the 90 001 (97.2% of total) participants without documented HF at baseline in these 13 trials generally produced similar results to the main analyses described above ( Supplementary material online, Table S1 ) although with fewer events available for pooling and consequent loss of power, the benefit of statin therapy over control therapy did not reach statistical significance.

also in 111,027 other papers